News
News

Cellnovo announces that Diabeloop is launching a CE marking Registration Study on Artificial Pancreas with Cellnovo pump

in portfolio news

Diabeloop, a privately held medical device company, developing an artificial pancreas system and Cellnovo Group (“Cellnovo” CLNV:EN Paris) a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announce today the launch of a CE marking cross-over registration study for the Artificial Pancreas solution developed by Diabeloop using the Cellnovo pump.

Subscribe